Nanotechnology’s increasing applications in the medical field are creating an opportunity for investors to participate in this emerging market, according to David Regan, CEO of Sona Nanotech (CSE:SONA,OTCQB:SNANF), a life science company based in Halifax, Nova Scotia.
“This innovation is where growth happens,” Regan said. “There’s been a ton of research that has gone into both the manipulation of nanotechnology and a great deal of work on immunotherapies for cancer patients.”
Sona Nanotech is developing its Targeted Hyperthermia, a photothermal cancer therapy that leverages Sona’s biocompatible gold nanorods, which are rod-shaped, non-toxic nanoparticles made of gold.
“We’re standing on the shoulders of that research to say, ‘Look, this is incredible information. How can we now bring it together and operationalize it for a therapy that will do good and that will really create an enhancement over what is currently done,” Regan said.
Watch the full interview with David Regan, CEO of Sona Nanotech, above.
The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Sona Nanotech and seek advice from a qualified investment advisor.
This interview may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, receipt of property titles, etc. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. The issuer relies upon litigation protection for forward-looking statements. Investing in companies comes with uncertainties as market values can fluctuate.